Respiratory depression and fatalities have been attributed to ethanol/buprenorphine (BUP) combination in drug addicts maintained with BUP/naloxone or BUP alone. The exact mechanisms of the ethanol/BUP interaction and the contribution to the toxicity of norbuprenorphine (NBUP), the main BUP metabolite with respiratory depressant properties are unknown. We investigated the sedative and plethsymographic effects resulting from the co-administration of intragastric ethanol (3 g/kg) and intravenous BUP (30 mg/kg) in Sprague-Dawley rats. We determined the whole blood pharmacokinetics of ethanol (using gas chromatography coupled to mass spectrometry), BUP and its metabolites (using liquid chromatography coupled to tandem mass spectrometry) and investigated the mechanisms of drug-drug interactions in the presence or absence of naloxone (7.5 mg/kg). Ethanol/BUP and ethanol/BUP/naloxone combinations significantly deepened sedation in comparison to BUP alone (P < .01) and BUP/naloxone (P < .05), respectively. Ethanol/BUP combination significantly increased the inspiratory time and decreased the minute volume in comparison to BUP alone (P < .01 and P < .01, respectively) and ethanol/BUP/naloxone (P < .05 and P < .01, respectively). Neither naloxone nor flumazenil reversed ethanol/BUP-induced sedation and respiratory depression. In the presence of ethanol, the area under the BUP concentration-time curve was significantly decreased (P < .05), BUP volume of distribution increased (P < .05) and the metabolic ratios of NBUP and norbuprenorphine-3-glucuronide increased (P < .01). In conclusion, the ethanol/BUP combination results in marked sedation and respiratory depression in the rat, prevented but not reversed by naloxone. Ethanol/BUP interactions are mainly pharmacokinetic resulting in increased NBUP production. Despite the non-reversal by naloxone and flumazenil of the effects attributed to the ethanol/BUP combination, protection provided by naloxone suggests an additional pharmacodynamic interaction.
. BUP/naloxone (NLX) combination (ratio 4:1) has been marketed to reduce diversion and abuse (Mendelson and Jones 2003) ; but its relevance remains debated (Hakkinen et al. 2013; Pedapati et al. 2011) . Additionally, the effectiveness of naloxone in reversing BUP-attributed central nervous system (CNS) depressant effects in overdose is still unclear due to the high affinity of BUP for the MOR (Mé garbane et al. 2010) .
BUP concentrations in fatalities are usually within the therapeutic range (Kintz 2001) . In autopsy cases where BUP had been detected, no significant differences in blood BUP concentrations and in the percentage of cases with positive ethanol detection were observed between fatalities attributed to BUP and fatalities where BUP was not the cause of death (Hakkinen et al. 2012; Selden et al. 2012) . These findings supported the proposition that neither ethanol nor BUP could separately explain the death onset, clearly suggesting drug-drug interactions between the molecules. Intuitively, a pharmacodynamic mechanism of interaction was suggested, ethanol targeting the c-aminobutyric acid (GABA)-A receptor and BUP targeting the MOR resulting in deleterious CNS consequences. Alternatively, the contribution of norbuprenorphine (NBUP), the major N-desalkyl BUP metabolite with established in vivo sedative and respiratory depressant effects in rodents (Alhaddad et al. 2011; Hreiche et al. 2013; Mé garbane et al. 2005; Ohtani et al. 1997 ) was suggested. Additionally, the possible deleterious role of glucuronide derivates including the NBUP-3-glucuronide, shown to bind to the opioid receptor subtypes in vitro and to exhibit sedative and respiratory effects in a mice model was examined (Brown et al. 2011) .
Therefore, we decided to characterize the deleterious interaction between ethanol and BUP and clarify its mechanism. We designed a rat study aiming (1) to describe the neurorespiratory effects resulting from the co-administration of ethanol and BUP in the presence or absence of NLX; (2) to study the reversal of the observed effects using flumazenil and naloxone, the 2 antidotes available at the bedside to treat poisoned patients; and (3) to determine the pharmacokinetics (PK) of ethanol, BUP and its active metabolites including NBUP and the glucuronide derivatives.
MATERIALS AND METHODS
The experiments were carried out within the ethical guidelines established by the National Institutes of Health and the French Ministry of Agriculture. Our protocols were approved by the Paris-Descartes University animal institutional ethics committee (N 15-081).
Animals. We used 7-8-week old male Sprague-Dawley rats weighing 250-300 g at the time of experiment (Janvier-labs, Genest, France). Animals were housed in well-ventilated cages at 20-22 C with 55 6 10% relative humidity and maintained under a 12-h dark/light cycle (light from 8:00 a.m. to 8 p.m.) for at least 1 week before the experiments. Food was provided ad libitum until 12 h before rat gavage with ethanol. Chemicals and drugs. For rat experiments, BUP hydrochloride, generously provided by Reckitt Benckiser (Massy, France) was diluted in 4% Tween V R (Sigma-Aldrich, St Quentin, France). Ethanol (Sigma-Aldrich, St Quentin, France) was diluted at 40% v/v in 0.9% NaCl. Flumazenil and naloxone hydrochloride dihydrate (Sigma-Aldrich, St Quentin, France) were diluted in 4% Tween V R . For the assays, BUP hydrochloride and NLX-3-glucuronide (Lipomed, Arlesheim, Switzerland) were diluted in methanol to obtain 1 and 0.1 g/l solutions, respectively. NBUP, BUP-3-glucuronide, NBUP-3-glucuronide, BUP-d4, NBUP-d4, and NLX-d5 (Cerilliant, Austin, Texas) were diluted in methanol to obtain 0.1 g/l solutions. NLX hydrochloride dihydrate (LGC, Molshein, France) was diluted in methanol to obtain a 0.81 g/l solution of anhydrous free base. Ammonium formate was purchased from Sigma-Aldrich (St Quentin, France). Methanol and acetonitrile [high-performance liquid chromatography (HPLC) grade] were purchased from Carlo Erbra (Val de Reuil, France). Water was deionized with a milli-Q ultrapure water system (Millipore Corp., Woburn, Massachusetts). Tert-butanol as ethanol internal standard (IS) was purchased from Sigma-Aldrich and diluted in ultra-pure water to obtain a 200 mg/l solution. The ethanol calibration curve was obtained using a multicomponent alcohol calibration kit (LGC Standards, Molshein, France). Medidrug Ethanol vb-plus 0.5 and 1.1 g/l used as quality controls were purchased from LGC standards. Sodium chloride was provided by VWR (Fontenay sous Bois, France).
Sedation measurement. Sedation was assessed in 4 stages from 0 (awake) to 3 (in coma), as previously described (Pirnay et al. 2008) . At stage 0, rats were completely awake and their gait and righting reflexes were intact. At stage 1, rats had reduced activity, showed light impairment of gait and an intact righting reflex with diminished muscular tonus. At stage 2, rats were asleep or static and showed reduced righting reflex. At stage 3, rats were comatose and did not have any righting reflex.
Surgery procedures. For the plethysmography study, a venous femoral catheter was inserted 4 days before the experiment to allow IV administration of the drugs. For the PK study, both venous and artery femoral catheters were inserted the day before the experiment to allow IV administration of the drugs and arterial blood sampling, respectively. For catheterization, the rat was anesthetized with intraperitoneal 70 mg/kg ketamine (Ketalar V R ) and 10 mg/kg xylazine (Rompum V R ) and placed on a warming blanket with regulating thermostat. The femoral vein and/or artery was catheterized using 30cm silastic tubing with external and internal diameters of 0.94 and 0.51 mm, respectively (Dow Corning Co., Midland, Michigan) as previously described (Cohier et al. 2014) . The catheter was subcutaneously tunneled and fixed at the back of the neck. Heparinized saline was injected to prevent thrombosis and catheter obstruction. Simultaneously, for the plethysmography study, a temperature transmitter (DSI, Chatillon, France) was implanted in the rat peritoneal cavity. Then, the rat was returned to its individual cage for a minimum 72 h recovery period and complete anesthesia washout.
Body temperature and plethysmography parameters measurement. Ventilatory parameters were recorded in a whole-body plethysmograph by the barometric method. On the day of experiment, the rat was placed in a rectangular Plexiglas chamber with a 3l volume connected to a reference chamber of the same size by a high-resistance leak to minimize the effect of pressure changes in the experimental room. The animal chamber was flushed continuously with humidified air at a rate of 5 l/min. During the recording periods, the inlet and outlet tubes were temporarily clamped and pressure changes associated with each breath were recorded using a differential pressure transducer (Validyne MP, 45 6 3 cmH 2 O, Northridge, California), connected to the animal and reference chambers. During each measurement, calibration was performed by 3 injections of 1ml air into the chamber. Room temperature was noted. The spirogram was recorded and stored on a computer with an acquisition data card (PCI-DAS 1000, Dipsi, Chatillon, France) using respiratory acquisition software (Acquis1 Software, CNRS, Gif-sur-Yvette, France) for analysis off-line.
The technique was validated daily with a series of leak tests (leak was considered when reduction in the signal amplitude exceeded 33% in 5 s). The quantification threshold corresponded to a minimum air volume injection of 30 ml. Within the range of tested volumes (0.1-3 ml), measurements were linear. The mean coefficient of intra-day variability (4 series of 5 measurements carried out the same day) was 1.32 6 0.18%. The mean coefficient of inter-day variability (25 measurements carried out on 3 different days) was 1.69 6 0.11%. We checked that the mean CO 2 measured using an Ohmeda 5250 RGM capnograph (rebreathing test) during clamping periods did not exceed 0.6% of the air contained in the chamber. During the experiment, the first measurement was performed after a 30-60 min period of accommodation, when the rat was quiet but not in deep or rapid eye movement sleep, grossly estimated from observing the behavior, response to noise, and pattern of breathing. The rat was then gently removed from the chamber for drug administration, and replaced in the chamber for the remaining measurements. Body temperature and ventilatory parameters were recorded at 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 150, 180, 210 and 240 min, each recording lasting about 60 s. We measured the tidal volume (V T ), the inspiratory time (T I ) and the expiratory time (T E ). Additional parameters were calculated including the respiratory frequency (f), the total respiratory time (T TOT ) and the minute ventilation (V E ¼ V T * f). At the end of the experiment, rats were euthanized with lethal intraperitoneal injections of pentobarbital.
Gas chromatography coupled to flame ionization detection (GC-FID). A chromatographic system including a Thermofinnigan Trace GC V R (Thermo Fisher Scientific, Villebon-sur-Yvette, France) was used to measure whole blood ethanol concentrations. The column used was a Hewlett Packard-Blood Alcohol (7.5 m Â 0.32 mm Â 20 mm; Chromoptic, Courtaboeuf, France). After warming at 85 C during 30 min, 1 ml of head space of sample was injected and eluted to the GC column. The GC column was initially held at 120 C during 1 min, then temperature was increased to reach 165 C at 25 C/min during 1.9 min and held 2.2 min at 165 C. Temperature of hydrogen/air flame was held at 250 C inside the flame ionization detector. Whole blood ethanol concentrations were quantified by using the peak area ratio between ethanol and the IS as previously described (Roussel et al. 2012) . The ratio was then calculated on the basis of calibration curves prepared each day (10-400 mg/l). Controls (50 and 110 mg/l) were included in each analytical batch. Liquid chromatography coupled to tandem mass spectrometry (LC-MS 2 ). LC-MS 2 analysis was performed with Agilent 1260 infinity HPLC system (Agilent Technology, Santa Clara, California) consisting of quaternary pumps, an autosampler and a vacuum degasser. Chromatographic separation was carried out using a Raptor TM biphenyl column [(100 mm x 3 mm (internal diameter); 2.7 mm (particle size)] (Restek, Lisses, France) with the corresponding guard column. The HPLC system was coupled to an API 3200 TM triple quadrupole mass spectrometer (Sciex, Framingham, Massachusetts) equipped with a turboV TM ion source operating in positive electrospray ionization. Instrument control and data acquisition were performed using Analyst V R 1.6 software (Sciex, Framingham, Massachusetts). The HPLC column was held at 30 C. The mobile phases consisted of a mixed solvent system of 0.25 mM aqueous ammonium formate with 0.1% formic acid (solvent A) and methanol (solvent B). Gradient elution was performed at a constant 800 ml/min flow rate as follows: 1 min equilibration followed by a linear decrease during 7 min from 95 to 5% of solvent A and 2 min maintained at 5% of solvent A. The system was then placed in the initial mobile phase conditions during 3.5 min to allow column washing. The injection volume was set at 80 ml in full loop mode. Autosampler was kept at 8 C. Detection was achieved using scheduled multiple reactions monitoring mode (MRM). Collision energies were adjusted to optimize surviving parent ions signal. Nitrogen was used as desolvation gas. Capillary voltage was set at 5500 V and source temperature at 500 C. Dwell time was 62.5 ms for each MRM transition. MRM transition states, cone voltages and collision energies optimized for each compound are presented as supplementary data. The described procedure was validated according to the internationally accepted recommendations. The limit of detection and the lower and upper limits of quantification for each compound are listed in the supplementary data. Whole blood samples from BUP-treated rats (50 ml), blank whole blood samples fortified with analytes for the calibration curve (1-5000 ng/ml) and quality controls (15, 150, and 1500 ng/ml) included in each analytical batch were spiked with 10 ml IS solution at 250 ng/ml. Methanol/acetonitrile was added to precipitate proteins and the samples were centrifuged at 18 213x g (12 700 rpm) for 10 min. One hundred ml of the supernatant was transferred to vials containing 300 ml sterile water and submitted to instrumental analysis. Each compound was quantified using the peak area ratio between the analyte and its respective IS. The drug concentrations were computed on the basis of calibration curves prepared each day.
Study Design
Dose regimen and drug administration. Ethanol (3 g/kg) was administered by gavage in rats fasted for at least 12 h to avoid significant variability in gastrointestinal ethanol absorption (Gentry 2000) . The dose of 3 g/kg ethanol was chosen as devoid of significant respiratory effects in rats, as previously published (Roussel et al. 2015) and checked in a preliminary study (data not shown), leading additionally to expected blood peaks in the range of concentrations usually found in BUP-attributed fatalities. BUP and BUP/NLX were administered by IV route to mimic crushed pill injection in drug addicts. The dose of 30 mg/kg BUP was chosen as devoid of respiratory effects in rats except for an increase in T I (Cohier et al. 2014 ). The 4:1 ratio of BUP/NLX combination (30 mg/kg to 7.5 mg/kg) was in agreement with the marketed Suboxone V R formulation. BUP or BUP/NLX was administered IV 30 min after the gavage at the previously reported ethanol peak time observed after intragastric (IG) administration (Jones et al. 1997; Roine et al. 1991) . To study the reversal of neurorespiratory effects related to ethanol/BUP combination, FLZ (10 mg/kg) and NLX (7.5 mg/kg) were injected at peak respiratory depression (i.e. 5 min after BUP administration). The IV dose of 10 mg/kg FLZ was chosen as it allows complete reversal of BZDrelated effects in rats (Cohier et al. 2014) .
Study 1-Neurorespiratory effects. Fasted rats were randomized into 5 groups (N ¼ 6/group) to receive ethanol þ 4% Tween, 0.9% NaCl þ BUP, 0.9% NaCl þ BUP/NLX, ethanol þ BUP or ethanol þ BUP/NLX. Subsequently, sedation, temperature and plethysmography parameters were measured during 240 min.
Study 2-Reversion of the neurorespiratory effects. Fasted rats received ethanol þ BUP and were randomized into 3 groups (N ¼ 6/ group) to receive 10 mg/kg FLZ, 7.5 mg/kg NLX or 4% Tween at 5min after BUP administration. Subsequently, sedation, temperature and plethysmography parameters were determined before (5 min) and after antidote administration (10, 15 and 20 min).
Study 3-PK analysis. Fasted rats were randomized into 5 groups (N ¼ 6-8 per group) to receive ethanol þ 4% Tween, 0.9% NaCl þ BUP, 0.9% NaCl þ BUP/NLX, ethanol þ BUP and ethanol þ BUP/NLX. Subsequently, serial arterial blood (130 ml) was sampled from each rat after the IG administration of ethanol or 0.9% NaCl (10, 20 and 30 min) and after the IV administration of BUP, BUP/NLX or 4% Tween (5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, 240, 300, and 360 min) . Whole blood was collected in heparinized microtubes and immediately frozen at À 20 C until analysis. Catheters were flushed each 40 min with heparinized saline to avoid thrombosis. The whole blood required for catheter flushing before each sampling was re-administered immediately after sampling to avoid significant blood loss and alterations in the measurement of concentrations at the late sampling times. We chose to measure concentrations in whole blood since available data in human fatalities have been measured in this matrix.
PK Modeling
Ethanol PK was determined after IG administration of 3 g/kg ethanol and analyzed using a non-linear mono-compartmental model with oral delay described by the following differential equation:
where C WB is ethanol concentration in V WB (apparent whole blood volume), k a the absorption rate constant of ethanol after IG administration, D the oral ethanol dose, and V M and K M the Michaelis-Menten constants for nonlinear ethanol elimination. The initial condition of Equation 1 was set to 0. BUP PK was determined after IV administration of 30 mg/kg and analyzed using a 2-compartmental model that fitted well the following equation:
, where C WB is the whole blood drug concentration at time t, the terms A and B the extrapolated zero intercepts, and a and b the apparent first-order elimination rate constants. The volume of distribution in the central compartment (V d ), the elimination half-life (t 1/2b ) and the clearance were calculated as follows: V d ¼ Dose/(A þ B), t 1/2b ¼ 0.693/kel, where kel is the overall elimination rate constant, and Cl ¼ V d *kel. BUP metabolites PK were described by a non-compartmental analysis. The best fitted line for the different models was selected after visual inspection of the predicted vs. observed and residual plots, the analysis of the objective function, the Akaike criteria and the precision of the estimates (mean and CV). PK parameters were determined as follows: C max and T max were the actual observed values. The area under the concentration-time curve from time zero to 360 min (AUC 0-360 ) was calculated using the trapezoid method and the area under the concentration-time curve from time zero to infinity (AUC 0-1 ) using the following equations:
Additionally, the whole blood NBUP-to-BUP concentration ratios were calculated at each sampling time and for each rat. The metabolic ratios were obtained by the sum of the metabolite concentrations divided by the sum of metabolites and parent molecules concentrations for each rat. The PK study was performed using WinNonlin software v.5.3 (Pharsight Corporation, California).
Statistical analysis. In the plethysmography study, T0 was the mean of the 3 baseline measurements. For each plethysmography parameter, we compared baseline values and values at each measurement time using a 2-way analysis of variance (ANOVA) for repeated measurements, followed by multiple comparison tests with Bonferroni's correction. To permit simultaneous analysis of the effect of time and various treatments, individual areas under the curve (AUC) for each parameter were calculated by the trapezoid method from T0 to 20 min and compared using one-way ANOVA followed by multiple comparison tests with Bonferroni's correction. To study reversal of respiratory effects, we compared the value of each plethysmography parameter at 5 min (i.e. before) and 10 min (i.e. after IV FLZ, NLX or solvent administration) using one-way ANOVA followed by Dunn's post-tests. PK parameters were compared using oneway ANOVA followed by Dunn's post-tests. In the plethysmography study, results are expressed as mean 6 SEM. In the PK study, concentrations are expressed as mean 6 SD and various estimated/calculated parameters as mean 6 CV. All tests were performed using Prism version 5.0 (GraphPad Software, Inc., San Diego, California). P values <.05 were considered as significant.
RESULTS

Study 1-Neurorespiratory Effects
Rats treated with ethanol þ BUP (P < .01) and ethanol þ BUP/NLX (P < .05) were significantly more sedated in comparison to the controls (Fig. 1) . In contrast, no significant difference in sedation was observed between rats treated with 0.9% NaCl þ BUP and 0.9% NaCl þ BUP/NLX. Temperature significantly decreased in rats treated with ethanol þ BUP and ethanol þ BUP/NLX in comparison to their respective controls (P < .001). In rats treated with ethanol þ BUP, temperature decreased at 5, 10, 15, 20, 25 and 30 min (P < .001), 40 and 50 min (P < .01) and 60, 180, and 210 min (P < .05); in rats treated with ethanol þ BUP/NLX, temperature decreased at 5, 10, 15, 20, 25, 30, and 40 min (P < .01) and 50, 60, 90, 120, 150, 180, 210 , and 240 min (P < .05).
In ethanol þ BUP (but not BUP/NLX), T I was significantly increased (AUC: P < .001) at 5, 10, and 15 min (P < .001), 20 min (P < .01), 120 and 150 min (P < .05) and 210 and 240 min (P < .001) in comparison to ethanol þ solvent, thus resulting in significant reduction in V E (AUC: P < .05). Co-administration of ethanol with BUP/NLX or BUP alone resulted in significantly different patterns of plethysmography parameters (Fig. 1) . When coadministering ethanol vs. 0.9% NaCl to BUP-treated rats, T I was significantly increased (AUC: P < .01) at 5 min (P < .001) and 10 and 15 min (P < .01) and V E reduced (AUC: P < .01) at 5 and 15 min (P < .01). When co-administering ethanol vs. 0.9% NaCl to BUP/NLX-treated rats, V T was significantly reduced (AUC: P < .001) at 5 min (P < .05) and 10 min (P < .05) but V E not significantly modified when comparing the AUCs. V E was only significantly reduced at 5 min in comparison to the baseline (P < .001). Co-administration of ethanol with BUP in comparison to BUP/ NLX resulted in a significant decrease in T I (AUC: P < .05) at 10 and 15 min (P <.001) and 20 min (P <.01), V T (AUC: P <.05) at 60 min (P <.001) and 90 min (P <.01) and V E (AUC: P <.01) at 15 min (P <.05).
Study 2-Reversion of the Neurorespiratory Effects
No reversion of the effects induced by the ethanol/BUP combination on rat sedation, temperature and plethysmography parameters was observed at 10, 15 and 20 min after the IV administration of 10 mg/kg FLZ or 7.5 mg/kg NLX in comparison to 5 min (i.e. the previously determined time of peak respiratory effects; figures presented in the supplementary data).
Study 3-PK Analysis
Regarding ethanol PK parameters, no significant differences were observed between the 3 rat groups receiving ethanol, i.e. and time 20 min post-injection. Comparisons were performed using ANOVA followed by multiple tests with Bonferroni's correction. *P < .05, **P < .01, ***P < .001. ethanol þ 4% Tween, ethanol þ BUP and ethanol þ BUP/NLX. Thus, ethanol PK parameters were determined using all concentrations obtained from these rats ( Fig. 2; Table 1 ). In the presence of ethanol, BUP concentrations were significantly lower at 5 min (P < .001), 10 and 20 min (P < .01), resulting in decreased AUC 0-360 (P < .05) and increased V d (P < .05) (Fig. 3, Table 2 ). Interestingly, the metabolic ratios of NBUP (P < .01) and NBUP-3-glucuronide (P < .01) were significantly increased in the presence of ethanol. The mean NBUP-to-BUP concentration ratios were in the [0.09-1.24] range and did not significantly vary in relation to the time and treatments received by the rats (Table 3) . However, although not significant, there was a trend to increased AUC of NBUP-to-BUP concentration ratio in the presence of ethanol (Fig. 4) . Additionally, NLX did not alter the effects of ethanol on the PK parameters of BUP and its metabolites.
DISCUSSION
Fatalities have been attributed to the concomitant exposure to BUP and ethanol in drug addicts (Ferrant et al. 2011; H€ akkinen et al. 2012; Seldén et al. 2012) . In our rat model mimicking the reported conditions of human exposure, we showed as previously assessed with benzodiazepines (Cohier et al. 2014) , that the ethanol/BUP combination is responsible for enhanced sedation and respiratory depression, however more limited in the presence of NLX.
In rats, neither BUP nor BUP/NLX resulted in respiratory depression, as previously shown (Chevillard et al. 2009; Cohier et al. 2014) , supporting the well-known BUP-attributed ceiling response and its preservation by NLX. However, in combination with ethanol, BUP resulted in rapid-onset but transient sedation and decrease in V E (duration: $20 min). Interestingly, in the presence of NLX, respiratory depression was more limited (duration: $5 min) while sedation was not modified. Our data suggested that NLX is able to limit the deleterious respiratory effects induced by ethanol/BUP in contrast to ethanol/diazepam combination (Cohier et al. 2014) . NLX-induced modifications to BUP-related plethysmography effects can be attributed to a certain degree of competition between these molecules at the MOR, although BUP affinity exceeded naloxone's at all opioidreceptor types (inhibitory constant: 0.08 nM for BUP vs. 0.93 nM for NLX, regarding MORs) (Emmerson et al. 1994; Raynor et al. 1994) . The ethanol/BUP combination was able to significantly increase T I , supporting the synergic/additional enhancing ethanol-related effects on the consistently reported BUPinduced T I increase (Chevillard et al. 2009 ). Interestingly, these effects, related to an action on breathing control centers, were prevented by NLX. Surprisingly, the ethanol/BUP combination in the presence of NLX significantly decreased V T , an effect attributed to either a central or direct peripheral action on inspiratory muscles. However, its exact mechanism remains to be determined.
In our rat model, the respiratory effects attributed to the ethanol/BUP combination were shortly observed up to 20 min post-BUP administration, while ethanol concentrations ranged between 190-198 mg/dl. In the reported human fatalities attributed to ethanol/BUP combination, ethanol concentrations ranged between 106 and 182 mg/dl (Ferrant et al. 2011 ; H€ akkinen Parameters were determined using a non-linear mono-compartmental model with oral delay. C max and T max , observed maximal concentration and peak time; et al. 2012). Taken together, these findings support that the deleterious respiratory effects due to ethanol/BUP combination are dependent on blood ethanol concentrations, even though at the elevated concentrations associated to their onset, ethanol is not life-threatening by itself. Additionally, ethanol induced a persistent decrease in body temperature in all treated rats whether administered alone or in combination with BUP or BUP/NLX. As previously observed , ethanol is well-known to decrease body temperature due to heat loss by peripheral vasodilation, inhibition of shivering thermogenesis due to muscle relaxation and CNS depression. Interestingly, diazepam that we previously studied in combination to BUP and BUP/NLX in rats was similarly responsible for temperature decrease in relation to the significant enhancement of sedation (Cohier et al. 2014) . These effects on temperature did not parallel BUP-induced effects on ventilation (peak of T I increase: $20 min).
We investigated the PK interactions between ethanol and BUP. BUP did not significantly alter ethanol peak or the timecourse of its blood concentration. Additionally, NLX did not lower blood ethanol concentrations, contrasting with previous questionable data (Badawy and Evans 1981) . Interestingly, in the presence of ethanol, BUP V d was increased and consequently the area under its concentrationtime curve decreased without additional alterations induced by NLX. Ethanol is known to damage the bilayer structure of cell membranes (Gurtovenko and Anwar 2009) and increase cell permeability to low-permeability drugs including opioids in monolayer cell cultures (Volpe et al. 2008) . Ethanol induces dose-dependent denaturation in the albumin protein in vitro with changes in the skeleton structure including conversion of intramolecular to intermolecular hydrogen-bonded betasheet and alterations in the microenvironment of tryptophan residues (Lin et al. 2004; Liu et al. 2010) . Due to direct interactions with specific hydrophobic binding sites (Avdulov et al. 1996) , ethanol increases the unbound fraction of various albumin-bound drugs as demonstrated with warfarine (Tatsumi et al. 2007) . Therefore, based on a reported $66%-binding rate to albumin (Nanovskaya et al. 2009 ), we hypothesized that ethanol-induces the displacement of the highly lipophilic BUP molecules from albumin's binding sites, which become readily available to cross the brain-blood barrier and contribute to enhanced CNS effects. The rapid and high tissue diffusion and the elevated lipophilicity of BUP may explain why in BUP-attributed fatalities, blood concentrations probably decrease rapidly to reach the therapeutic range while post-mortem brain, kidney and liver concentrations are much higher and better correlated with toxicity (Gaulier et al. 2000; Kintz 2001 ).
We found that ethanol induces significant increase in NBUP and NBUP-3-glucuronide metabolic ratios. Ethanol metabolism increases the reduced-to-oxidized nicotinamide adenine dinucleotide (NADH/NAD) ratio (Cederbaum 2012) , diminishing the liver UDP-glucuronic acid required to produce BUP glucuronide derivates and thus increasing BUP desalkylation to NBUP. Consistently, ethanol was shown to inhibit morphine glucuronidation to morphine-3-glucuronide in rat hepatocytes (Bodd et al. 1986) . Morphine reduced to morphine-3-glucuronide was similarly observed in the presence of ethanol in heroin-related fatalities (Polettini et al. 1999) . TABLE 2. Pharmacokinetic Parameters of Buprenorphine (BUP), Norbuprenorphine (NBUP), BUP-3-Glucuronide and NBUP-3-Glucuronide in 4 Groups of Rats Receiving Intragastric (IG) 0.9% NaCl þ Intravenous (IV) 30 mg/kg BUP, IG 0.9% NaCl þ IV 30 mg/kg BUP/7.5 mg/kg Naloxone (NLX), IG 3 g/kg Ethanol þ IV 30 mg/kg BUP or IG 3 g/kg Ethanol þ IV 30 mg/kg BUP/7.5 mg/kg NLX Each group consisted of 6-8 rats. Parameters were determined using a 2-compartmental model. Comparisons were performed using one-way ANOVA followed by Dunn's post tests. *P < 0 .05, **P < 0 .01 for ethanol þ BUP vs. 0.9% NaCl þ BUP. C max and T max , observed maximal concentration and peak time; k a , absorption rate constant; k 12 and k 21 , elimination rate constants from the different compartments; k el , overall elimination rate constant; V d , volume of distribution in the central compartment; Cl, clearance; T1/2b, half-life elimination; AUC0-360 min, area under the concentration-time curve from time zero to 360 min; AUC0-1, area under the concentration-time curve from time zero to infinity. Table 3 . Determination of Norbuprenorphine-to-Buprenorphine (BUP) Concentration Ratios in the Whole Blood in Relation to the Sampling Time Following BUP Administration in 4 Groups of Rats Receiving Intragastric (IG) 0.9% NaCl þ Intravenous (IV) 30 mg/kg BUP, IG 0.9%NaCl þ IV 30 mg/kg BUP/7.5 mg/kg Naloxone (NLX), IG 3 g/kg Ethanol þ IV 30 mg/kg BUP and IG 3 g/kg Ethanol þ IV 30 mg/kg BUP/7.5 mg/kg NLX Norbuprenorphine-to-buprenorphine concentration ratios in the whole blood Each group consisted of 6-8 rats.
In the largest series of 182 BUP-attributed fatalities, blood concentrations of BUP and NBUP were found in the 0.2-100 and 0.2-89 ng/ml ranges, respectively resulting in NBUP-to-BUP ratios of 0.056-10 (Hakkinen et al. 2012). Interestingly, maximum BUP and NBUP concentrations measured 10 min after IV injection of 16 mg BUP in volunteers were 137.7 6 18.8 ng/ml and 3.7 6 0.7 ng/ml, respectively (Huestis et al. 2013) . In some fatalities, relatively high plasma and tissue NBUP concentrations were found (Gaulier et al. 2000) , suggesting NBUP contribution to BUP-attributed death whereas in other cases, NBUP concentrations were surprisingly low, suggesting rapid death onset after BUP exposure and before much BUP metabolism to NBUP (Bardy et al. 2015) . NBUP is a potent respiratory depressor with $10 fold greater depressant activity than BUP (Ohtani et al. 1995) . Dosedependent ventilatory depression was obtained following NBUP administration in rats (Mé garbane et al. 2006; Ohtani et al. 1997) while sedation and decrease in the tidal volume were observed with NBUP-3-glucuronide in mice (Brown et al. 2011) .In rats, BUP was shown to be protective against NBUP-related depressive effects on ventilation (Mé garbane et al. 2006) . Plasma NBUP-to-BUP ratios resulting in the onset of such protective effects ranged from 7.83 6 1.95 to 10.04 6 3.27. In our study, the whole blood NBUP-to-BUP concentration ratios ranged from 0.09 to 1.24 with no significant differences in relation to the timecourse and co-treatments received by rats (i.e. in the presence or not of CNS depression). Although a trend to increased NBUP-to-BUP concentration ratios was observed in the rat blood in the presence of ethanol, brain concentrations of BUP and NBUP may more likely predict the onset of CNS toxicity than their ratio in the peripheral blood, considering that ethanol increases NBUP and NBUP-3-glucuronide production and enhances BUP V d .
Pharmacodynamic interactions between opioids and ethanol have also been suggested to explain the worsened CNS effects resulting from their combination. Ethanol exerts its CNS effects by non-selectively disordering ligand-gated ion channels such as GABA-A and glutamate receptors (Dopico and Lovinger 2009 ). In our study, respiratory depression resulting from the ethanol/BUP combination did not involve the benzodiazepine ligand site of GABA-A receptors, since no reversal using FLZ was obtained. However, GABA-A receptors are known to be important CNS targets of ethanol (Kumar et al. 2009 ) and may thus be involved by other binding sites. Interestingly, RO15-4513, a GABA-A (a4b3d) receptor antagonist was shown to reverse ethanol-induced sedation (Wallner et al. 2014) . The authors proposed a model in which b3-and d-containing GABA receptors present a unique ethanol site at the a4/6þb3-subunit interface. We did not assess the effectiveness of this GABA-A receptor antagonist to reverse ethanol/BUP combination-related respiratory effects.
Rat studies showed that acute intake of ethanol is able to release endogenous opiate peptides in the brain (Jarjour et al. 2009; Méndez et al. 2010) . Deleterious CNS effects induced by ethanol/BUP combination may thus result from the combination of the effects of the exogenous opioid (i.e. BUP) and the effects of the endogenous opioids released by ethanol. Interestingly, although quite questionable, NLX effectiveness to antagonize ethanol-induced narcosis was reported in rats (Badawy and Evans 1981) and humans (Sørensen and Mattisson 1978) . In our study, NLX did not reverse the respiratory depression attributed to the ethanol/BUP combination even though it was administered at its peak onset. However, when BUP was combined with ethanol in the presence of NLX, significantly reduced respiratory depression was observed. BUP exhibits slow association with the MOR (equilibration time: $30min) (Boas and Villiger 1985) , allowing NLX to act on the MOR (Canestrelli et al. 2014) and block BUP effects (Shannon et al. 1984; Tzschentke 2002) . To date, NLX usefulness and optimal dose regimen to reverse BUP-attributed CNS depression remains a matter for debate.
Finally, ethanol was shown in volunteers to significantly reduce the genioglossal muscle activity (Robinson et al. 1985) and consequently increase the upper airway resistance (Krol et al. 1984) . Ethanol was also shown to inhibit neuromuscular transmission in the rat phrenic nerve-diaphragm preparation, via pre-and postjunctional mechanisms (Wali and Hayter 1988) . All these findings suggest that respiratory depression induced by the ethanol/BUP combination may result from BUPinduced alteration in the adapted response of the brainstem ventilation control centers to ethanol-induced upper airway obstruction and diaphragm dysfunction. However, this hypothesis remains to be demonstrated. Our study has significant limitations. It may have been underpowered to show some differences between the studied groups. However, since we used 6-8 rats/group for each experiment, we believe that where real differences were not assessed by our study, they would not be clinically pertinent. We did not investigate respiratory effects by blood gas analysis able to assess the ultimate drug-induced respiratory depression; however, modifications in the plethysmography parameters remain useful to clarify the nature of possible drug-drug interactions and show compensatory physiological mechanisms developed to avoid drug-related deleterious consequences. Additionally, although our naïve outbred rat model receiving acute administrations of BUP and ethanol may not reflect the exact situation of the opioid-dependent drug addicts who may consume ethanol for prolonged time and thus present various changes in their metabolism and cell receptor expression, we believe that our study represents a first step to help understanding ethanol/BUP interaction that may even occur in non-opioid-dependent individuals (Ferrant et al. 2011) .
CONCLUSION
An ethanol/BUP combination is responsible for neurorespiratory depression in the rat, more limited in the presence of NLX, however not reversed by FLZ or NLX, the 2 antidotes available at the bedside. In addition to possible pharmacodynamic interactions, ethanol increases NBUP production which may contribute to the deleterious effects of the ethanol/BUP combination. Our study supports the benefit of the NLX/BUP combination in comparison to BUP to limit CNS depression that may result from ethanol/BUP coexposure.
SUPPLEMENTARY DATA
Supplementary data are available at Toxicological Sciences online.
